Can Small Hepatocellular Carcinoma be Cured by Percutaneous Acetic Acid Injection Therapy? by Fan, S.-T.
340 HPB INTERNATIONAL
ment either on the day of their operation or one
day later. The issue at hand now is to compare
laparoscopic cholecystectomy to "small-inci-
sion" cholecystegtomY in a properly designed
trial, in such a setting.
References
[1] Barkun, J. S., Barkun, A. N. and Sampalis, J. S. et al. and
the McGill gallstone treatment group. (1992).
Randomised controlled trial of laparoscopic versus mini
cholecystectomy, Lancet, 340, 1116-19.
[2] McMahon, A. J., Russel, I. T. and Baxter, J. N. et al.
(1994). Laparoscopic versus minilaparotomy cholecys-
tectomy: a randomised trial, Lancet, 343, 135-38.
[3] McGinn, F. P., Miles, A. J. G., Uglow, M., Ozmen, M.,
Terzi, C. and Humby, M. (1995). Randomized trial of
laparoscopic cholecystectomy and mini-cholecystect-
omy, Br. J. Surg., 82, 1374-77.
[4] McMahon, A. J., Russell, I. T. and Ramsay, G. et al.
(1994). Laparoscopic and minilaparotomy chole-
cystectomy: A randomized trial comparing postopera-
tive pain and pulmonary function, Surgery, 115,
533- 539.
[5] Wherry, D. C., Rob, C. G., Marohn, M. R. et al. (1994). An
external audit of laparoscopic cholecystectomy per-
formed in medical treatment facilities of the Depart-
ment of Defense, Ann. Surg., 220, 626- 634.
Charles J. Yeo, MD
Professor of Surgery
Johns Hopkins University
School of Medicine
Blalock 606
600 N Wolfe Street
Baltimore, MD 21287- 4606
United States of America
Can Small Hepatocellular Carcinoma be Cured
by Percutaneous Acetic Acid Injection Therapy?
ABSTRACT
Ohishi, K., Nomura, F., Ito, S. and Fujiwara, K. (1996)
Prognosis of small hepatocellular carcinoma (less than 3cm)
after percutaneous acetic acid injection: Study of 91 cases.
Hepatology; 23, 994-1002.
To assess the efficacy of ultrasound (US)-guided
percutaneous acetic acid (in concentrations of 15%,
20%, 30%, 40%, and 50%) injection for small
hepatocellular carcinomas (HCCs) for long-term
prognosis, percutaneous acetic acid injection using
15% to 50% acetic acid was performed in 91 patients
with one to four HCCs smaller than 3 cm during the
past 6.5 years. During the series of treatment
sessions for each patient, the same concentration of
acetic acid was used. All tumors could be treated
successfully with percutaneous acetic acid injection
despite the differences in acetic acid concentration
used. The number of treatment sessions to treat
similar size of tumor was less when the higher
concentration of acetic acid was used. No serious
complications occurred as a direct sequela to
percutaneous acetic acid injection. None of the
tumor treated regrew. The 1-, 2-, 3-, 4-, and 5-year
survival rates for91 patients were 95%, 87%,80%, 63%,
and 49%, respectively. The 1-, 2-, 3-, 4-, and 5-year
cancer-free survival rates of these patients were 83%,
54%, 50%, 37%, and 29%, respectively. Both liver
function and size of tumor affected both survival rate
and cancer-free survival rate significantly, but the
number oftumors did not. The concentration of acetic
acid did not affect the survival rate. Percutaneous
acetic acid using 15% to 50% acetic acid will be
effective therapy for small HCCs for long-term
prognosis. (Hepatology 1996; 23, 994-1002).
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PAPER DISCUSSION
The study by Ohnishi et al. [1] recommended
that acetic acid is the preferred agent to absolute
alcohol because acetic acid has the property ofHPB INTERNATIONAL 341
extracting collagen and probably good penetra-
tion into cancer cells in the tumour capsule or
intratumour septa. Thus the number of sessions
required to completely necrose the hepatocellu-
lar carninoma (HCC) was reduced, the incidence
of local recurrence was less and the survival was
longer compared with patients treated by
percutaneous alcohol injection as reported in
the. literature. The result is commendable,
especially for patients with Child’s A liver
function. However, not mentioned in the report
is whether patients with Child’s A function had
been offered surgical resection since they con-
stituted almost 70% of the series. Although
surgical resection was shown in a non-rando-
mized and retrospective study [2] to achieve a
comparable result with percutaneous alcohol
injection, partial hepatectomy should not be
discarded especially for lesions located at the
surface of liver. In that situation, the lesion is not
suitable for percutaneous alcohol or acetic acid
injection whereas partial hepatectomy would be
much safer and more efficacious.
Although almost half of the patients treated
by percutaneous acetic acid injection survived 5
years, the cancer-free survival rate was only
29%, indicating that recurrence or new growth is
the intrinsic problem in treatment of HCC,
irrespective of modality. Since all the hepato-
cytes have been inflicted by the same carcino-
genic agent, intrahepatic recurrence would be
invariable and a radical treatment could not be
possible without liver transplantation. Liver
transplantation was shown to produce a much
better result than resection if the HCC is <5 cm.
[3]. However, in the face of organ shortage,
many patients with small HCC have to be
treated by non-surgical means even though the
liver function is suboptimal. The method sug-
gested by Ohnishi et al. [1] is certainly a step
forward in the non-operative treatment of HCC
and can ’buy’ time before an organ is available.
Prevention of intrahepatic recurrence follow-
ing surgical or non-surgical treatment is the aim
of all surgeons and physicians looking after
patients with HCC. Adjuvant treatment with
chemoembolization was shown to be effective
but that was a non-randomized and retrospec-
tive study [4]. The authors had not mentioned
whether percutaneous acetic acid had been
given to new HCC that developed after the
initial treatment. I believe that they had done so.
However, the crux of the problem does not lie on
how good is the treatment method but depends
on the hepatocarcinogenic potential of the hepa-
tocytes of the liver remnant. Polyprenoic acid,
by its action of promoting apotopsis and, matura-
tion of hepatoma cell line was shown to reduce
development of second primary HCC after
hepatectomy or percutaneous alcohol injection
[5]. If proven to be of value, it would be the drug
for patients with treated HCC and even for high
risk individuals for the development of HCC.
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